520 completed, 190 recruiting, 177 terminated, 130 unknown. 1255 Phase 1, 423 Phase 2.
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Not yet recruiting | Istituto Oncologico Veneto IRCCS | 14 | 2027-01-31 | 2026-11-03 |
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma SYS6055 - Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | 384 | 2026-12-15 | 2026-10-29 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
Showing 20 of 1255. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (673) · Lymphoma, Follicular (475) · Burkitt Lymphoma (437) · Lymphoma, Mantle-Cell (431) · Lymphoma, Non-Hodgkin (425) · Leukemia, Lymphocytic, Chronic, B-Cell (391) · Lymphoma, B-Cell, Marginal Zone (364) · Lymphoma (347) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (304) · Lymphoma, Large-Cell, Immunoblastic (201) · Hodgkin Disease (200) · Waldenstrom Macroglobulinemia (179) · Recurrence (176) · Leukemia (151)
Hemic and Lymphatic Diseases (1255) · Neoplasms by Histologic Type (1249) · Immune System Diseases (1245) · Immunoproliferative Disorders (1245) · Lymphatic Diseases (1245) · Lymphoproliferative Disorders (1235) · Neoplasms (1193) · Lymphoma (908) · Lymphoma, Non-Hodgkin (830) · Hematologic Diseases (605) · Pathological Conditions, Signs and Symptoms (550) · Pathologic Processes (549) · Disease Attributes (536) · Leukemia, Lymphoid (519)
Cyclophosphamide (192) · Rituximab (186) · fludarabine (84) · Prednisone (72) · Vincristine (71) · Lenalidomide (60) · Etoposide (59) · Doxorubicin (58) · fludarabine phosphate (58) · ibrutinib (38) · Filgrastim (36) · Bendamustine Hydrochloride (34) · Peripheral Blood Stem Cell Transplantation (33) · venetoclax (33) · Cytarabine (32)
National Cancer Institute (NCI) (117) · M.D. Anderson Cancer Center (35) · Fred Hutchinson Cancer Center (27) · City of Hope Medical Center (26) · Memorial Sloan Kettering Cancer Center (22) · Mayo Clinic (18) · Celgene (14) · Hoffmann-La Roche (13) · Northwestern University (13) · Masonic Cancer Center, University of Minnesota (12) · Second Affiliated Hospital, Zhejiang University, School of Medicine (12) · Novartis Pharmaceuticals (11) · Institute of Hematology & Blood Diseases Hospital, China (10) · National Institutes of Health Clinical Center (CC) (10) · AstraZeneca (9)
United States (835) · China (241) · France (88) · Spain (85) · United Kingdom (84) · Australia (73) · Italy (70) · Germany (62) · Canada (61) · South Korea (48) · Japan (40) · Belgium (31) · Poland (31) · Netherlands (25) · Israel (22)
Ajay Gopal (8) · James N Kochenderfer, M.D. (5) · Nirav Shah, MD (5) · Cheng Qian, PhD (4)
PMID 34515338, PMID 41671463, PMID 34398557, PMID 34780125, PMID 35622074, PMID 39813680, PMID 34687939, PMID 37486616, PMID 39319495, PMID 40195173, PMID 40802906, PMID 19949018, PMID 20028764, PMID 22002018, PMID 25317870, PMID 25381051, PMID 27482888, PMID 28054442, PMID 30518502, PMID 31527168, PMID 32499241, PMID 33308471, PMID 33512414, PMID 33888899, PMID 34310745, PMID 34312556, PMID 34321836, PMID 34493319, PMID 34889384, PMID 35799791, PMID 36375120, PMID 36821767, PMID 37774014, PMID 38376944, PMID 39351902, PMID 40367950, PMID 42341322, PMID 42411504, PMID 42541678, PMID 10552943, PMID 10632319, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15570084, PMID 16061911
2023 (22), P30CA033572 (20), 2015 (12), 2016 (11), 2018 (11), P30CA015704 (11), U01CA076576 (10), 2025 (9), P30CA015083 (9), U01CA097452 (9), 2017 (8), P30CA006973 (6), P30CA016058 (6), P30CA016672 (6), P50CA107399 (6)